International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.
Parthenogenetic (from the Greek parthenos meaning “virgin” and genesis meaning “birth”) activation utilizes unfertilized human eggs to create parthenogenetic stem cells (hpSC) that can be immune-matched to millions of people. As a result, a relatively small number of hpSC lines could provide enough immune-matched cells to cover a large percentage of the world’s population.
ISCO’s scientists are focused on using hpSC to treat severe diseases of the nervous system, joints and liver where cell therapy has been proven clinically effective but is limited by the availability of safe immune-matched human cells.